Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects
Sponsor: Onconic Therapeutics Inc.
Summary
This study aims to evaluate the Efficacy and Safety of JP-1366-based Triple-Therapy in H. pylori-positive Subjects
Official title: A Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Non-inferiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects
Key Details
Gender
All
Age Range
19 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
414
Start Date
2026-11-01
Completion Date
2028-10-06
Last Updated
2026-10-15
Healthy Volunteers
No
Conditions
Interventions
JP-1366 20 mg, Lansoprazole 30 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg
Orally, twice daily
Lansoprazole 30mg, JP-1366 20 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg
Orally, twice daily